There is scope within clinical practice to use CGM for individuals without Type 1 diabetes, which would include Type 2 diabetes, if they use insulin and experience either severe hypoglycaemia or ‘unstable blood glucose levels that are causing concern’4; however, current evidence for this recommendation or further use in Type 2 diabetes is lacking. This evidence concerns the gene INS and type 2 diabetes mellitus.